A regulatory committee of the European Medicines Agency is urging approval of the oral therapy Jascayd (nerandomilast) in the European Union for treating adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), two forms of the respiratory disease. While the European Commission — which makes all final…
News
Two Phase 3 clinical trials testing Tyvaso (treprostinil) in people with idiopathic pulmonary fibrosis (IPF) both met their main goals, showing that the inhalation therapy significantly outperformed a placebo at slowing the decline in lung function among IPF patients. With these data in hand, Tyvaso’s developer, United…
Brainomix, a health software company, and drug developer Boehringer Ingelheim will advance testing of an artificial intelligence (AI)-based tool that may enable earlier diagnosis of progressive pulmonary fibrosis (PF). The two companies are collaborating to run studies of the Brainomix 360 e-Lung, a U.S. Food…
Insilico Medicine will soon launch an early clinical trial in China to test an inhaled version of its therapy candidate rentosertib in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF). This announcement follows the clearance of the company’s investigational new drug (IND) application by the Chinese Center for…
Enrollment has finished ahead of schedule in a Phase 2 clinical trial testing Calluna Pharma‘s experimental antibody therapy CAL101 in people with idiopathic pulmonary fibrosis (IPF). The Phase 2 study, dubbed AURORA (NCT06736990), was designed to enroll about 150 adults…
Abnormalities in DNA methylation — a type of genetic modification that can alter the activity of a gene without changing its sequence — may affect a person’s risk of developing idiopathic pulmonary fibrosis (IPF), according to a new study. The researchers say this work has uncovered “novel roles” for…
A protein called PIEZO1, which helps cells in blood vessels detect mechanical forces, plays a key role in driving pulmonary fibrosis (PF), a new study indicates. Findings suggest that blocking the activity of PIEZO1 and the signaling pathway it controls may be a useful strategy for developing new…
The U.S. Food and Drug Administration (FDA) has approved a generic version of Ofev (nintedanib) for easing lung scarring in people with idiopathic pulmonary fibrosis (IPF). The new generic nintedanib oral capsules, available in 100 mg and 150 mg dosages, will be marketed by Cipla. In a…
A compound called orcinol glucoside (OG) can reduce lung inflammation and scarring in mouse and cell models of idiopathic pulmonary fibrosis (IPF), according to the findings of a new study, which suggests that OG could prove to be a treatment for the lung condition. The lab study results indicate…
Treatment with Tyvaso (treprostinil) outperformed a placebo at preserving lung function and preventing clinical worsening — meaning, it led to gains beyond temporary symptom changes — among people with idiopathic pulmonary fibrosis (IPF) in the now-completed global TETON-2 clinical trial. United Therapeutics, Tyvaso’s developer and the study’s sponsor,…
